Instil Bio (TIL) Total Current Liabilities (2020 - 2026)
Instil Bio (TIL) posted quarterly Total Current Liabilities of $4.7 million for Q1 2026, down 34.67% year-over-year from $7.2 million in Q1 2025, and down 2.48% quarter-over-quarter from $4.8 million in Q4 2025.
Instil Bio (TIL) Total Current Liabilities (2020 - 2026) Analysis & Trends
Instil Bio's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 34.67% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (down 34.67% YoY), while the FY2025 annual figure was $4.8 million, down 38.67% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $4.7 million, down from $4.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $43.2 million in Q2 2022, with the low at $4.7 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $11.4 million (2024), against an average of $17.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 112.28% in 2022, then slumped 68.01% in 2023.
- Instil Bio's Total Current Liabilities stood at $32.8 million in 2022, then slumped by 67.8% to $10.6 million in 2023, then retreated by 25.22% to $7.9 million in 2024, then slumped by 38.67% to $4.8 million in 2025, then dropped by 2.48% to $4.7 million in 2026.
- Business Quant data shows TIL's Total Current Liabilities at $4.7 million in Q1 2026, $4.8 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Instil Bio | 50.29 Mn | 50.29 Mn | - | 3.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.31 Mn |
| Mar 31, 2026 | 4.72 Mn |
| Dec 31, 2025 | 4.84 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 13.85 Mn |
| Mar 31, 2025 | 7.23 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | 10.29 Mn |
| Mar 31, 2024 | 11.35 Mn |
| Dec 31, 2023 | 10.56 Mn |
| Sep 30, 2023 | 13.47 Mn |
| Jun 30, 2023 | 18.38 Mn |
| Mar 31, 2023 | 26.69 Mn |
| Dec 31, 2022 | 32.79 Mn |
| Sep 30, 2022 | 42.10 Mn |
| Jun 30, 2022 | 43.21 Mn |
| Mar 31, 2022 | 36.78 Mn |
| Dec 31, 2021 | 41.36 Mn |
| Sep 30, 2021 | 32.09 Mn |